Long-term data from the Phase III JUPITER-02 trial demonstrates toripalimab, combined with chemotherapy, significantly extends overall survival for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). After six years of follow-up, median overall survival reached 64.8 months in the toripalimab arm, a 31-month improvement compared to chemotherapy alone. Toripalimab is the first immunotherapy approved for NPC in Europe, indicated for first-line treatment in combination with chemotherapy for adult patients with advanced disease not amenable to surgery or radiotherapy.
The JUPITER-06 trial focused on esophageal squamous cell carcinoma (OSCC), a prevalent cancer particularly in Asian regions. The final analysis, with a median follow-up of 14.2 months, revealed a significant improvement in overall survival for patients receiving toripalimab plus chemotherapy compared to chemotherapy alone (17.7 months vs. 12.9 months). Toripalimab is approved in Europe for first-line treatment of unresectable advanced, recurrent, or metastatic OSCC when combined with cisplatin and paclitaxel.
Biomarker analysis in JUPITER-06 identified copy number alteration-corrected TMB (ccTMB) and the EGIC classification as potential predictors of long-term survival benefit with toripalimab-based combination therapies. These findings suggest that specific genomic profiles may help identify patients most likely to benefit from this treatment approach. The safety profile of toripalimab in both trials remained manageable, with no new safety signals emerging during extended follow-up.